December 2, 2025
Investors and strategic partners expect technical risk when evaluating early-stage drug development programs. However, certain CMC (Chemistry, Manufacturing, and Controls) red flags are immediate causes for concern—and can quickly lower valuations, delay deals, or even derail partnerships altogether. Here are five of the most common CMC issues that investors view as […]
